Ken Griffin Fulcrum Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 52,800 shares of FULC stock, worth $315,744. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,800
Previous 332,100
84.1%
Holding current value
$315,744
Previous $2.24 Million
77.78%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding FULC
# of Institutions
136Shares Held
43.7MCall Options Held
3.12MPut Options Held
128K-
Rtw Investments, LP New York, NY5.85MShares$35 Million0.89% of portfolio
-
Cowen And Company, LLC3.71MShares$22.2 Million1.18% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.85MShares$17 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$15.2 Million0.0% of portfolio
-
Trv Gp Iv, LLC Boston, MA2.34MShares$14 Million10.72% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $311M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...